Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06821191 · ClinicalTrials.gov registry record · Phase 4

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

A Phase 4 study of Coronary Artery Disease, sponsored by University of Florida.

Recruiting
Registry status
Phase 4
Development phase
78
Enrollment target
1
Study location

NCT06821191 is a Phase 4 study of Coronary Artery Disease that is actively recruiting participants, run by University of Florida. The registered enrollment target is 78 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06821191, a Phase 4 study of Coronary Artery Disease, is actively recruiting participants, sponsored by University of Florida.

RECRUITING
Registry status
Phase 4
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

Dual antiplatelet therapy (DAPT) with low-dose aspirin and a P2Y12 inhibitor is the current standard of care in patients with coronary artery disease experiencing an acute event or undergoing percutaneous coronary intervention. However, the ischemic benefits are counterbalanced by a significant increase in bleeding events. Over time, different DAPT de-escalation strategies have been developed to reduce the bleeding risk while maintaining the ischemic protection, but there is currently no head-to-head comparison between them. The purpose of this clinical trial is to conduct a head-to-head comparison on the pharmacodynamic efficacy of DAPT de-escalation by dose reduction to low-dose prasugrel (5 mg od) and DAPT de-escation by switching from standard-dose more potent P2Y12 receptor inhibitor to standard-dose clopidogrel (75 mg). To determine if the PD profiles of these two strategies are comparable, we aim to conduct a non-inferiority study.

Conditions Studied

Coronary Artery Disease

Interventions

  • DRUG clopidogrel 75 mg
  • DRUG Prasugrel 5 mg

Study Locations (1)

Florida

  • University of Florida - Jacksonville

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2025-03-10
Est. Completion 2027-01-07
Phase Phase 4

Sponsor

University of Florida

1,106 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06821191

The ClinicalTrials.gov registry entry for NCT06821191 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (94% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which clopidogrel 75 mg is the first listed.

NCT06821191 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06821191 about?

NCT06821191 is a clinical study titled "Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study". Dual antiplatelet therapy (DAPT) with low-dose aspirin and a P2Y12 inhibitor is the current standard of care in patients with coronary artery disease experiencing an acute event or undergoing percutaneous coronary intervention. However, the ischemic benefits are counterbalanced by a significant incr...

What is the current status of trial NCT06821191?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2025-03-10. Estimated completion is 2027-01-07.

What conditions does trial NCT06821191 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT06821191?

The interventions under investigation include: clopidogrel 75 mg (DRUG), Prasugrel 5 mg (DRUG).

Who is sponsoring clinical trial NCT06821191?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06821191 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.